Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

BACKGROUND: Despite the positive impact of targeted therapies on metastatic renal cell carcinoma (mRCC), durable responses are infrequent and an unmet need exists for novel therapies with distinct mechanisms of action. We investigated the combination of recombinant Interleukin 21 (IL-21), a cytokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatia, Shailender, Curti, Brendan, Ernstoff, Marc S, Gordon, Michael, Heath, Elisabeth I, Miller, Wilson H, Puzanov, Igor, Quinn, David I, Flaig, Thomas W, VanVeldhuizen, Peter, Byrnes-Blake, Kelly, Freeman, Jeremy A, Bittner, Rachel, Hunder, Naomi, Souza, Sonia, Thompson, John A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019894/
https://www.ncbi.nlm.nih.gov/pubmed/24829759
http://dx.doi.org/10.1186/2051-1426-2-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019894/
https://www.ncbi.nlm.nih.gov/pubmed/24829759
http://dx.doi.org/10.1186/2051-1426-2-2

Ejemplares similares